MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.
暂无分享，去创建一个
P. Zinzani | J. Pagel | K. Izutsu | C. Cheah | A. Mato | M. Balbas | M. Palomba | M. Barve | P. Ghia | C. Ujjani | E. Lech-Maranda | B. Fakhri | S. Gouill | T. Eyre | T. Fenske | Jonathon B. Cohen | J. Woyach | N. Lamanna | J. Gerson | D. Lewis | K. Lewis | X. Tan | D. E. Tsai | Michael L. Wang | Y. Koh | Manish R Patel | Catherine C Coombs | I. Flinn | Alvaro J Alencar | N. N. Shah | W. Jurczak | Constantine S Tam | S. Sundaram | M. Yin | B. Nair